GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - SPRUCE BIOSCIENCES INC

Explicit Guidance:

• Regulatory Timeline: Plans to submit a Biologics License Application (BLA) to the FDA in December; anticipated FDA acceptance in February; target for FDA approval (and eligibility for a Pediatric Review Voucher) in late August/early September.
• Manufacturing: Completion of the second Process Validation and Qualification (PPQ) run for drug substance and drug product by the end of the current year; submission of the second PPQ analytical report during the FDA review cycle.
• Clinical Trials: Confirmation trial (registration study) is already underway at the time of BLA submission; no requirement for full patient recruitment prior to product launch.
• European Launch: Revamping European commercialization initiative to begin in Q4 of the current year.

Business-Segment Outlook:

• Commercial Market Size: Preliminary claims database analysis identifies approximately 1,400 patients with MPS III in the US, with an estimated 450 diagnosed patients specifically with the MPS3B subtype.
• Treatment Reach: Expectation to treat not only young children but also older patients/young adults where the goal is disease stabilization rather than reversal.
• Patient Access Strategy: Utilization of Salesforce and Medical Science Liaison (MSL) teams focused on the 15 NORD-approved lysosomal storage disease centers of excellence in the US (5 of which are MPS-specific).
• Global Commercialization: Exploring multiple European frameworks including local distributors, partners, or name-patient programs to achieve global availability.

Market and Competitive Outlook:

• Pricing Expectations: Anticipating a price range between $1 million and $4 million per patient per year, positioning the product based on value rather than weight-based dosing (unlike competitor Denali's $2.8M+ potential for 80kg adults).
• Competitive Landscape: No other products currently being approved for MPS3B; the market is described as "clamoring" for a life-transforming therapy, with the drug's mechanism (tralcinase alpha) being unique due to neuronal and lysosomal penetration.
• Market Differentiation: Competitive advantage derived from fixed-dose, every-other-week administration schedule versus weight-based competitors.

Macro / Industry Outlook:

• Regulatory Precedent: Citing the FDA's full approval of Denali's Fayuvi (MPS3A) as a regulatory precedent for approval via biomarker endpoints (Heparin Sulfate) and the non-residual ANTS biomarker as a "reasonably likely to predict clinical benefit."
• Pricing Pressure: Acknowledgment of "sensible" pricing to ensure patient access while commensurately charging for the severity of the disease state.

Strategic Initiatives:

• Monetization: Intent to monetize the Pediatric Review Voucher (PRV) upon approval to fund US commercialization; proceeds will be retained by Spruce Biosciences, not transferred to Biomarin.
• Ongoing Payments: Modeling royalty and sales milestone payments to Biomarin, estimating $20–$30 million in payments to Biomarin over the first two years of net sales.
• Data Release: Scheduled presentation of new, previously unpublished biomarker data (NFL, GM2, GM3) at a world meeting in February in San Diego.
• Expanded Access: An expanded access program is operational to allow patient access to the product between now and commercial availability.

Risks and Headwinds to Outlook:

• Disease Heterogeneity: Acknowledgment of patient variability in disease stages and decline rates, though management states modeling (propensity score matching) adequately addresses baseline imbalances.
• Regulatory Review: While not explicitly detailing an ADCOM requirement, the outcome remains subject to FDA final determination on the acceptance of the biomarker as a primary endpoint for approval.
• European Uncertainty: European regulatory environment described as "becoming more difficult," necessitating flexible commercial frameworks.
• Manufacturing Complexity: Transition of drug product manufacturing site from Veteran Germany to Samsung Biologics (South Korea) required additional qualification and PPQ processes.

Management Tone on the Future:

• High Confidence: Management describes the regulatory pathway as "very tight," "very clear," and the clinical package as "incredibly compelling" and "super strong."
• Strategic Certainty: Expresses confidence that the BLA submission will meet standards and that the FDA has signaled no need for an Advisory Committee (ADCOM) review.
• Alignment: Notes strong alignment with the FDA regarding the registration trial design and the "big win" of having the trial underway at submission rather than at launch.

Miscellaneous:

• Drug Characteristics: Tralcinase alpha is a unique enzyme replacement therapy with a fission protein tagged with truncated IGF-2, delivered via a port and myo-reservoir into the CSF.
• Data Integrity: Emphasis on the "proprietary" nature of the natural history study (unlike external control arms often used in rare diseases) which was initiated by Biomarin and completed prior to acquisition.